NRX Pharmaceuticals Stock Discussion

been holding for4 years 😢

$NRX Pharmaceuticals (NRXP.US)$ Here is why OCGN will skyrocket 400% to 800% over the next 9 to 12 months.
What is OCU400's market potential? If we take Ocugen's estimates seriously, it is mouthwatering. The biotech projects that OCU400 could earn approval in 2026. Ocugen thinks the therapy could generate between $30 billion and $47 billion in total revenue in the five years after approval. The company's market cap is about $488 million as of this writing. So by any standar...

Encouraged by these results, NRx Pharmaceuticals plans to seek accelerated FDA approval for NRX-101 for patients with bipolar depression at risk of akathisia.
Catching the attention of the pharmaceutical industry and investors alike, NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage pharmaceutical company, has announced final clinical trial results showcasing a superior safety profile of NRX-101 over lurasidon...